Attovia Therapeutics (ATTO) vs Cullinan Therapeutics (CGEM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Attovia Therapeutics is the larger company by market cap ($690.3 million vs $577.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATTO | CGEM |
|---|---|---|
| Share price | $15.10 | $8.89 |
| Market cap | $690.26M | $577.15M |
| 1-day change | -3.08% | -1.98% |
| YTD return | — | -14.11% |
| 1-year return | — | -6.12% |
| 5-year return | — | -51.21% |
| EPS (TTM) | $-5.53 | $-3.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-219.88M |
| 52-week high | $28.00 | $23.19 |
| 52-week low | $12.94 | $8.47 |
| Distance from 52-week high | -46.07% | -61.66% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +186.09% | +285.49% |
| Average volume | 337.27K | 997.14K |
| Shares outstanding | 45.71M | 64.92M |
| Employees | 50 | 109 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Attovia Therapeutics
ATTO stock →Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 50 employees
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
ATTO vs CGEM FAQ
Which is bigger, Attovia Therapeutics or Cullinan Therapeutics?
Attovia Therapeutics (ATTO) is larger, with a market capitalization of $690.26M compared with $577.15M for Cullinan Therapeutics (CGEM).
Are Attovia Therapeutics and Cullinan Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.